A NDROGENS, PRIMARILY TESTOSTERONE and dihydrotestosterone, are the major class of steroid hormones that develop and maintain male reproductive physiology. In consequence, lack of androgen receptor, for example, results in a feminized, pseudohermaphrodite phenotype and invariably results in infertility. However, initial development of the testis, which is required for subsequent masculinization, does not require the involvement of androgens (1, 2) .
The role of estrogen and estrogen receptors (ERs) in the development and maintenance of the male reproductive tract remains provocative and unclear. To date, two nuclear ERs have been described, ER-␣ (3) and ER-␤ (4). Mice deficient in aromatase, the enzyme responsible for the formation of estrogens, although initially fertile, develop progressive Leydig cell abnormalities later in life with concomitant impairment in spermatogenesis (5) . Aromatase-deficient male humans may have oligozoospermia and immotile spermatozoa (6, 7) . The discovery and phenotypic evaluation of a man with a null mutation in his ER-␣ genes (8) who has apparently normal testes and normal sperm density but decreased viability of his spermatozoa, in conjunction with the targeted disruption of ER-␣ and ER-␤ in the mouse (9, 10) , all suggest that estrogens can have a selective biological effect on the male reproductive system.
The predominant ER within the human male testis is likely to be ER-␤ (11) , which is expressed in spermatogonia, spermatocytes and early developing spermatids. These authors were not able to detect ER-␣ expression in testis. ER-␣ is present in noncilliated epithelial cells in the efferent ductules and in the epithelial cells of the epididymis (12) , although again ER-␣ was not detected within the testis. Both ER-␣ protein and mRNA have been detected in spermatozoa. Immunocytochemistry located ER-␣ to the tail of spermatozoa, suggesting a direct involvement of this receptor in an estrogen-mediated, rapid, nongenomic sensing that spermatozoa are present within the female reproductive tract (13) .
Moreover, ERs may be responsive not only to estrogens but also to other chemically diverse compounds, in particular to some androgens, phytoestrogens, and to environmental estrogens, which have all been demonstrated to have some estrogenic activity (14) .
The generation of ER-␣ transcripts in humans is complex and subject to the activity of several distinct promoters (15) . At present, a total of six human ER-␣ promoters are known, and these generate transcripts that differ in their 5Ј-untranslated regions (UTRs) (15) (16) (17) . The 5Ј exon associated with individual promoters are then spliced to a common splice acceptor site located at position ϩ163 bp relative to the transcription start site generated by the most proximal ER-␣ promoter (15) (16) (17) (18) (19) (20) (21) .
Alternative promoter usage may account for the differential expression of ER-␣ in a wide variety of tissues, which, in addition to testis, is present in reproductive tissues such as ovary and uterus (18) and in mammary gland (19) . ER-␣ is also expressed in the pituitary and central nervous system (20) , bone (21, 22) , vascular tissue (23), liver (18) , and adipose tissue (24) . The plethora of alternative promoters may not only act to determine the tissue distribution of ER-␣, but also to regulate the abundance of receptor within cell types (25) . This level widely varies, for example, from relatively high levels in breast carcinoma cell lines (26) , lower levels of expression in the female reproductive tract (27) , to even lower expression in bone (21) .
We examined the promoter usage involved in the expression of ER-␣ in testis to confirm that mRNA encoding ER-␣ was indeed present in testis and to determine if this occurred in a tissue-specific way. The products obtained by primer extension analysis of testis mRNA using a primer from the coding sequence of ER-␣ were found to be of a different size compared with the products obtained from uterus and from MCF-7 cells. Cloning and sequence analysis of these products indicated that the 5Ј end of ER-␣ transcripts in human testis did not correspond to any known ER-␣ promoter activity. Further, S1 nuclease protection analysis confirmed that these novel transcripts were expressed in testis. RT-PCR of defined tissues isolated from the male reproductive tract indicates that this promoter is active in testis and in epididymal tissue but not in prostate. The genomic location of this testis/ epididymis specific promoter was located approximately 16 kb from the common splice site at position ϩ163 relative to the originally described transcriptional start site (3).
Materials and Methods

Human tissues/organs
The testis material was obtained from a 69-yr-old man who underwent surgery for prostatic carcinoma. There is no information available on his fertility status or on his hormone levels, and he was not treated with antiandrogens before surgery. Epididymis was obtained from a 73-yr-old patient, who also had prostatic carcinoma and who was also not treated with antiandrogens before surgery. Again, his fertility and hormone status are not known. The epididymis was carefully dissected from the testis, according to Yeung et al. (1991 and 1993 , Refs. 28 and 29, respectively) with the scissors rinsed as appropriate during this procedure to avoid contamination between tissues that were cut into the different parts of the epididymis. The separation from caput and corpus was made between sampling sites 1 and 2, the corpus extended to just beyond sampling site 4, and the cauda included region 5. Human testis, uterus, and prostate RNA was obtained from CLONTECH Laboratories, Inc. (Palo Alto, CA).
Primer extension
Primer extension was performed by an improved RACE technique, entitled PEETA, as described previously (30) . In essence, total RNA was either isolated from cells using TRIzol (Invitrogen, Carlsbad, CA) or, in the case of testis RNA, purchased from CLONTECH Laboratories, Inc. A PCR product, encompassing the initiating AUG of human ER-␣ p66 to residue 126, was amplified from pHEO (31) using biotin-atgaccatgaccctccacaccaaagcatctggg as a forward primer and gctggccgtggggctgcaggaa as a reverse primer. This product was bound to magnetic beads coated with streptavadin (Dynal, Oslo, Norway) and the noncoding strand removed by alkaline denaturation. An internal extension primer (tctgaccgtagacctgcgc, Fig. 1 ) was annealed to the biotinylated strand which was then used as a template for the generation of a highly radiolabeled primer. This primer was released from the streptavadin beads by alkaline treatment and hybridized to 30 g of total RNA. This primed template was extended by 50 U of Expand reverse transcriptase (Roche Molecular Biochemicals, Mannheim, Germany), the products denatured and resolved on an 8% denaturing polyacrylamide/urea gel.
S1 analysis
Single-stranded DNA probes for S1 nuclease protection analysis (32) , encompassing from their 5Ј end, 100 bp of vector-derived sequence, promoter-specific exon sequence [either A (62 bp), T1ϩT2 (340 bp) or T1 (86 bp)] and 295 bp of human ER-␣ sequence downstream of ϩ163 splice acceptor site (see Fig. 3 ) were generated from constructs made in the pCR2.1 cloning vector (Invitrogen). Briefly, biotinylated M13 forward primer (biotin-ctggccgtcgttttac) was used in conjunction with an ER-␣ reverse primer, ctcacaggaccagactccataatggta, to amplify each specific probe from the appropriate template. The product was bound to streptavidin-coated magnetic beads (Dynal) and the nonbiotinylated strand removed by alkaline denaturation. An internal primer, tctgaccgtagacctgcgc, was annealed to the immobilized strand and extended with T7 DNA polymerase in the presence of [␣-
32 P]-deoxy-CTP (Amersham Pharmacia Bioetech, Little Chalfont, Buckinghamshire, UK). The resulting probe was eluted from the beads by alkaline denaturation, purified from a denaturing gel and 10 5 cpm hybridized overnight at 55 C with 30 g of total RNA. S1 nuclease digestion was then carried out as described by Ausubel et al. (33) . Protected fragments were detected by autoradiography following resolution on an 8% denaturing polyacrylamide gel.
Tissue culture and transfections
All cell lines were maintained in DMEM (Invitrogen) containing 10% fetal bovine serum (Invitrogen) at 37 C with 5% CO 2 . Charcoal dextranstripped serum was used at 2.5% concentration in phenol red-free DMEM when required. Promoter constructs were generated by PCR using a single reverse primer in conjunction with several forward primers to generate fragments of the testis promoter 250 bp, 750 bp, 1 kb, and 2 kb in size. The sequence of the reverse primer used was cgcgct agccaggcaagagagctcgtgaaagag and the forward primers were gcgggtacctccacactcattctattcacatcttttg (250 bp), gcgggtaccgtgccatttaatatctggggacctc (750 bp), cgcggtaccccaaagtggtgggccagagttctc (1 kb), and cgcggtaccaagatatgttcactttcctggctg (2 kb). The amplified products were directionally cloned as KpnI/NheI fragments into pGL2 basic (Promega, Southampton, UK). Cultured cells, in 6-cm 2 dishes, were transfected with 5 g of testis/epididymis promoter construct and 0.25 g of a Renilla luciferase expressing plasmid using the CaPO 4 method (34). Cells were plated at densities such that about 80% confluency was achieved at the assay endpoint. Cells were allowed to attach overnight, changed to either 10% fetal calf serum (FCS) containing media, stripped media or stripped media supplemented with estradiol (E2) for 24 h after which fresh media was again added for a further 24 h. The cells were then transfected with DNA and assayed for luciferase after a further 72 h.
Promoter specific RT-PCR
RNA was isolated from human uterus, distal cauda, proximal corpus, caput and whole testis using TRIzol (Invitrogen) as described by the manufacturer. An outline of the nested PCR, along with the location of the primer used in the primer extension protocol, is detailed in Fig. 1 . Total RNA was then primed using a primer (P3) complementary to the mRNA sequence located in the 3Ј UTR of the ER-␣ gene (GATTATCT-GAACCGTGTGGGAGCCAGGGAG) and reverse transcribed using MuLV reverse transcriptase (Roche Molecular Biochemicals) according to the first strand synthesis protocol given by the manufacturer. A nested PCR protocol was necessary to consistently obtain the 2.0-kb testis promoter specific product from these samples. One microgram of reverse transcribed mRNA was used as a target in a 50-l first-round PCR with the RT primer P3 described above and a testis promoter specific forward primer P1 (TTGCCTGCCGCCATGTAAGAA). A second-round PCR amplification was then carried out on 1 l of the first-round PCR using FIG. 1. Schematic representation of the location of primers used in the specific amplification of the ER-␣ mRNA arising from testis promoter activity. The relative position of the radiolabeled primer used in the initial primer extension analysis is also shown. the reverse primer P4 (CTCTCAGACTGTGGCAGGGAAACC) in conjunction with an inner testis promoter specific primer P2 (GCGCCTT-TGCTCTTCCTTT). Products were then resolved on a 1.2% agarose gel.
Results
A radiolabeled primer encompassing the initiating AUG of the ER-␣ open reading frame to nucleotide ϩ225 was used in a primer extension protocol with total RNA isolated from MCF-7 cells and from testis, prostate and uterine tissue. Yeast tRNA was used as a control for specificity. Extended products were obtained with each human derived total RNA (Fig.  1) . The major product in MCF-7 cells, representing around 70% of the total extended products, was subsequently found, following cloning and sequence analysis, to result from utilization of the A promoter. In contrast, many extended products were obtained with uterine RNA, indicating that, as previously demonstrated (17), multiple promoters contribute to the pool of ER-␣ mRNA in this tissue. The major mRNA species in uterus however are derived from A and C promoter activity. Prostate predominantly expressed mRNA species resulting from the A and C promoters, albeit with ER-␣ mRNA levels in this tissue at around 50-fold less abundance than in uterus or in MCF-7 cells. More interestingly, two novel extended products were observed with testis RNA, again at a relatively low abundance compared with ER-␣ transcripts present in uterus or in MCF-7 cells. These products, along with the major bands subsequently found to be the product of A and C promoter usage in uterus, were excised, poly dC tailed, amplified, cloned, and sequenced, as previously described (30) .
Sequence analysis of the longer testis extension product (237 bp of unique sequence 5Ј to the common splice acceptor site) and the shorter testis extension product (87 bp of unique sequence 5Ј to the common splice acceptor site) indicated that the 5Ј region of these mRNAs had no similarity to any previously known ER-␣ gene products. Further, the shorter sequence was present at the 5Ј end of the long extension product, suggesting that the longer testis sequence arises through incomplete or alternative splicing during the generation of these mRNA species (Fig. 2A) . This was confirmed by amplifying a PCR product from human genomic DNA using a forward primer derived from the short testis sequence in conjunction with a reverse primer from the unique part of the longer sequence. The resulting product, following cloning and sequencing, demonstrated that there are two 5Ј noncoding exons that can be present in ER-␣ mRNA resulting from testis promoter activity. The exon adjacent to the testis promoter is named as T1 with the longer, alternatively spliced exon named T2. T1 and T2 are separated from each other by a short (101 bp) intron.
A blast search of the human genome using either T2 or T1 as query sequence identified a contig, 67346 bp in size (EMBL accession no. AL356311) located at 6q25.1-26 of chromosome six. Complete homology between both query sequences and part of this contig occurs on the minus strand between positions 10134 to 10049 (T1 exon) and positions 9948 to 9769 (T2 exon). Contig AL356311 also contains the first coding exon of ER-␣ and the four previously identified ER-␣ promoters located within a 4-kb region 5Ј to initiating ATG of exon 1. The genomic sequence confirms that the T1 and T2 exons are separated by a 101-bp intron. A schematic representation of the testis promoter within the genomic context of ER-␣ is shown in Fig. 2B . The major core promoter elements of the ER-␣ testis promoter, determined using weighted matrices as defined by Bucher (35) , are shown in Fig. 2C . Although a CAAT box was not present in the ER-␣ testis promoter, a GC box, with the potential to bind the general transcription factor Sp1 and a TATA box, directing recruitment of RNA polymerase II to the promoter, are present in this sequence with very high homology to their respective consensus sequence elements. The major transcription start site, defined experimentally by the initial primer extension analysis, is positioned 23 nucleotides downstream from the TATA box. Numerous potential transcription factor binding sites were detected by computer analysis of the ER-␣ testis promoter (36) . The relevant sequence, including 100 bp of the promoter sequence, exon T1, the 101-bp intron and exon T2, are available in the EMBL Nucleotide Sequence Database under accession no. AJ421639.
The tissue-specific utilization of the testis promoter was
FIG. 2. Primer extension of RNA isolated from MCF-7 cells (an ER
positive breast carcinoma cell line), testis, prostate, and uterus gave rise to specific extended products. Those marked with an asterisk were excised, tailed, amplified by PCR, cloned, and sequenced as previously described (30) . This analysis identified the "A" and "C" promoters that have been previously characterized. These proximal promoters were active in all tissues tested; however, two novel sequences were isolated from testis RNA. Untreated probe and probe hybridized with yeast tRNA served as negative controls.
then evaluated using a highly sensitive modified S1 nuclease protection assay (32) . Three probes (Fig. 3A) , encompassing the A, T2, and T1 5ЈUTRs were used to specifically detect ER-␣ mRNA species derived from A and testis promoter activity. The A promoter contributed to the pool of ER-␣ mRNAs present in MCF-7 cells and in all of the tissues (testis, prostate, and ovary) examined. However, expression of the testis promoter, evaluated for both splice variants, demonstrates that this promoter is most active in testis. In contrast, expression is weak in prostate with no detectable expression found in MCF-7 cells (Fig. 3B) . Surprisingly, two specific protected bands, of similar intensity, were obtained with the T1 ϩ T2 probe. As we had limited amounts of defined tissue from the male reproductive tract, nested RT-PCR was used to evaluate testis promoter utilization in human distal cauda, proximal corpus, caput epididymis, testis, and in uterus. We were able to amplify a 2.0-kb product corresponding to fulllength ER-␣ in all tissues apart from uterus (data not shown). Testis/epididymis ER-␣ promoter constructs of 2, 1 kb, and 750 and 250 bp were then generated from genomic DNA using a series of primers designed upstream of the ϩ1 transcription start site as defined by the initial primer extension experiments. These promoters were cloned into pGL-2 basic, a promoter-less luciferase expression vector. The resulting constructs were then transfected into HeLa and HepG2 cells and luciferase levels determined 72 h after transfection. The basal activity of the parental vector pGL-2 was evaluated and all experiments were corrected for transfection efficiency using a Renilla luciferase-expressing plasmid, driven from the cytomegalovirus immediate early promoter, as an internal transfection control. Experiments were performed in triplicate and results are presented as a mean with sd. The series of testis/epididymis promoters clearly function well in both cell lines (Figs. 4 and 5) , with the 1-kb promoter construct around 1000-fold more active than the empty reporter construct in HeLa cells and the 250-bp construct approximately 400-fold more active than parental vector in HepG2 cells. Promoter activity in cells growing in media supplemented with 10% FCS was consistently around 5-to 10-fold higher than cells grown in media containing dextran/charcoal stripped FCS. The addition of E2 or dihydroxytestosterone to media containing charcoal/dextran-stripped serum failed to restore promoter activity. Clearly, some other soluble factor(s), removed during dextran/charcoal treatment of FCS, is able to induce a strong response from the ER-␣ testis/epididymis promoter. Elements located between ϩ1 kb to ϩ2 kb of the testis/epididymis promoter have an inhibitory effect on activity in both HeLa and HepG2 cells. In HepG2 cells   FIG. 3 . The structure of the two testis-specific ER-␣ mRNA splice variants (T1 and T1ϩT2) are shown in Fig. 2A . The 87-bp exon associated with the testis promoter transcription start site is present in both forms of the testis ER-␣ mRNA. However, this exon can be alternatively spliced to either the T2 exon or directly to the first coding exon of ER-␣. The genomic organization of the ER-␣ T promoter is illustrated in Fig. 2B . The T promoter lies approximately 16 kb upstream of the common splice acceptor site in the first coding exon of the ER-␣ gene and is associated with the T1 exon, which is separated from the T2 exon by an intron 100 bp in size. Alternative splicing results in the T2 exon either being present or skipped in ER-␣ mRNA resulting from T promoter usage. Readily identifiable core promoter elements of the testis ER-␣ promoter are shown in Fig. 2C . Also shown is the major transcription start site identified by the initial primer extension analysis of testis RNA.
most of the core promoter activity resides in the first 250 nucleotides upstream from the transcription start site, whereas in HeLa cells promoter activity decreases with size up to 1 kb of the transcription start site.
Discussion
Primer extension analysis, using a highly sensitive protocol (30) was used to determine if an unidentified promoter was involved in the expression of ER-␣ in testis. Unlike nuclease protection assays or RT-PCR, techniques that have been previously employed to detect ER-␣ mRNA in testis, primer extension does not rely on having complete prior knowledge of the nucleic acid sequence under investigation. The primer used was entirely 3Ј to the common splice acceptor used by every ER-␣ promoter that has been identified to date, thereby increasing the likelihood of detecting novel transcripts. Two extended products, of sizes different from those arising from promoters used in MCF-7 cells, prostate or uterus, were present at low abundance. These were excised, tailed, amplified by PCR, cloned, and sequenced. The 5Ј UTRs of the two testis products had not been previously identified and were likely to arise from the activity of novel promoters. Of note is that a third extended product was obtained with testis RNA and was found to result from "A" promoter activity, the promoter that lies most proximal to the first coding exon of the ER-␣ gene. It may be useful to analyze additional tissues with this procedure, in particular, pituitary, brain, and smooth muscle, where ER-␣ is believed to   FIG. 4 . The tissue-specific expression of the testis promoter was evaluated by S1 analysis. Probes were designed that detect individual ER-␣ mRNA 5Ј UTRs as shown in Fig. 3A . Vector-derived sequence was included to discriminate between undigested probe and protected fragments. A total of 295 nucleotides of sequence downstream from the common splice acceptor site at ϩ163 was also included in the probe to detect the total amount of ER-␣ mRNA present in the sample. Figure 3B demonstrates that, whereas the "A" promoter is used in every tissue evaluated, expression of the testis promoter is most active in testis.
play a significant role in normal physiology or in pathology and where additional promoters to those already described may have a role in the tissue-specific expression of ER-␣ mRNA.
Sequence analysis revealed that both novel testis transcripts were likely to result from a single promoter followed by alternative, or incomplete splicing of the resulting precursor mRNA, as the longer extended product contained an additional 237 bp between the unique 5Ј UTR present in the shorter product and the splice site present in the first coding exon of the ER-␣ gene (see Fig. 2 ). This is reminiscent of exon F1 in the mouse ER-␣ gene, which can alternatively splice to a common splice acceptor site located at position ϩ119 in the first coding exon or to exon F2, located between exon F1 and the first coding exon (37) . As with all other ER-␣ promoters described to date, the 5Ј UTR region resulting from testis/ (Fig. 4B) . In HeLa cells, the shorter promoters function well but this activity is considerably reduced when charcoalstripped media, even when supplemented with E2, is used. The 2-kb promoter is much less active than the shorter forms. These promoters are also active in HepG2 cells, but the reduction in activity with length is less pronounced than in HeLa cells.
epididymis promoter activity splices to the common splice site at position ϩ163. However, other splicing options within the human ER-␣ gene also available, as for example, human exon F can either splice to ϩ163 or can skip coding exon 1 and splice to the beginning of coding exon 2, resulting in a transcript that expresses a truncated ER-␣ isoform, 46-kDa in size (38) .
The genomic location of the novel testis 5Ј UTRs could be placed on a contig (67,346 bp in size) from chromosome 6, which also contained the first coding exon and the proximal promoter cluster of the ER-␣ gene. This further strengthens our suggestion that we have discovered a new promoter for the expression of ER-␣ mRNA. The testis promoter lies between four adjacent promoters that are found within a 2-kb region immediately upstream of the initial coding exon and very distal promoters (16) 39) , the ER-␣ gene encompasses a sizable genetic unit that may contain further promoters and alternative coding exons. It is possible that some ER-␣ promoters require to be separated from each other by a significant distance so that epigenetic events involved in either the activation or suppression of individual promoters during differentiation apply to a single promoter and do not affect other promoters, as chromosome condensation associated with epigenetic silencing usually extends over a minimum of several kilobase pairs (40) .
Nuclease protection assays using probes designed to detect ER-␣ mRNA variants with 5Ј UTR sequences corresponding to exon A, T1, and T2 screened against a limited panel of RNA isolated from human tissues indicated that the T promoter gives rise to significant ER-␣ mRNA in testis with weak expression seen in uterus, in prostate, or in MCF-7 cells. Two protected bands of similar intensity were obtained with the T1 ϩ T2 S1 probe, indicating that two mRNA species, differing in the length of their 5Ј UTR, result from testis promoter activity. The size of the lower species indicates that the shorter product contains all of exon T2. It is not possible from our analysis to know if additional sequence, specifically the 101-bp intron between exons T1 and T2, can be present in an ER-␣ transcript arising from testis promoter activity in addition to the species where exon T1 is directly spliced to position ϩ164. If this were the case, it implies that three mRNA variants result from the testis promoter, namely a long form consisting of exon T1, the 100-bp intron and exon T2 then spliced to the common splice acceptor site at ϩ163; a splice variant where the 100 intron is not present and a short splice variant where exon T1 is spliced directly to ϩ163. We further examined testis promoter utilization within the male reproductive tract using RNA prepared from microdissected human distal cauda, proximal corpus, and caput epididymis and testis. Although there was insufficient RNA to perform an S1 nuclease protection assay with these samples, we were able to amplify by nested RT-PCR a 2.0-kb product encompassing the testis promoter specific 5ЈUTR to exon 8 of the ER-␣ gene. No product was obtained with mRNA prepared from uterus (data not shown). We provide evidence that mRNA encoding ER-␣ is present within the testis and epididymis. There is considerable debate as to the level of ER-␣ protein found within the testis, although ER-␣ has been detected in the epididymis (12) . There are six initiation codons before the initiation codon used in the translation of the ER-␣ open reading frame, suggesting that translational control may provide another regulatory point in the expression of ER-␣ from mRNA transcripts arising from the testis/epididymis promoter.
The data obtained with PEETA, S1 nuclease protection assays and RT-PCR strongly indicate that the T promoter is a tissue-specific promoter responsive to factors produced only in testis and epididymal tissue. These observations contrast with the strong activity observed in transient transfections of the core T promoter in the cell types tested (HeLa and HepG2, Fig. 4 ; NTERA, MCF-7 and Cos cells, data not shown). Further, the activity of the T promoter was around 10-fold higher than the proximal A promoter or the distal F promoter in HeLa and HepG2 cells grown in complete media (data not shown). The activity of the testis/epididymis promoter was severely impaired when sequences upstream of approximately Ϫ1 kb were included in the promoter, indicating that repressor elements in this distal promoter region interact with transcription factors to suppress promoter activity. Also, epigenetic effects in vivo, such as DNA methylation and chromatin condensation, could inhibit promoter expression when present in chromatin, and this may act to preclude promoter activity in cell types other than testis and epididymis.
In conclusion, we have identified and partially characterized a novel ER-␣ promoter that is used in the expression of ER-␣ in testis and in the epididymis. This observation provides further support for the hypothesis that estrogens, through the classical ER-␣ receptor, play a role in the male reproductive tract.
